Encouraging physician appropriate prescribing of non-steroidal anti-inflammatory therapies
| ISRCTN | ISRCTN43532635 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN43532635 |
| Secondary identifying numbers | N/A |
- Submission date
- 02/08/2004
- Registration date
- 10/08/2004
- Last edited
- 29/10/2021
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Signs and Symptoms
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Mr Malcolm Doupe
Scientific
Scientific
Primary Health Care Research Unit
St Boniface Research Centre
Winnipeg, Manitoba
R2H 2A6
Canada
| mdoupe@sbrc.ca |
Study information
| Study design | Randomised controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | GP practice |
| Study type | Quality of life |
| Scientific title | Encouraging physician appropriate prescribing of non-steroidal anti-inflammatory therapies |
| Study acronym | MAAUI |
| Study objectives | Not provided at time of registration |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Chronic pain |
| Intervention | All primary care physicians in Manitoba, Canada have been randomly assigned to a control group or an intervention study group. The educational intervention being evaluated consists of an audit and feedback mechanism combined with optional participation in a Continuing Medical Education interactive workshop. The primary outcome of the study is the change, from pre- to post- intervention, in physicians' appropriate prescribing of non-steroidal anti-inflammatory therapies for patients requiring chronic treatment. Three classes of non-steroidal anti-inflammatory therapies have been identified: a new class of non-steroidal anti-inflammatory agents known as coxib therapy, traditional non-steroidal anti-inflammatory drug (NSAID) monotherapy, and traditional NSAID therapy combined with gastro-protective agents. Appropriate prescribing is defined based on international clinical practice guidelines and the provincial drug reimbursement policy in Manitoba. |
| Intervention type | Other |
| Primary outcome measure | Not provided at time of registration |
| Secondary outcome measures | Not provided at time of registration |
| Overall study start date | 01/11/2000 |
| Completion date | 01/01/2004 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Not Specified |
| Target number of participants | Not provided at time of registration |
| Key inclusion criteria | All primary care physicians in Manitoba, Canada |
| Key exclusion criteria | Not provided at time of registration |
| Date of first enrolment | 01/11/2000 |
| Date of final enrolment | 01/01/2004 |
Locations
Countries of recruitment
- Canada
Study participating centre
Primary Health Care Research Unit
Winnipeg, Manitoba
R2H 2A6
Canada
R2H 2A6
Canada
Sponsor information
Merck Frosst Canada and Co. (Canada)
Industry
Industry
C.P. 1005
Pointe-Claire-Dorval
Quebec
H9R 4P8
Canada
| lorijean_manness@merck.com | |
"ROR" |
https://ror.org/028979q34 |
Funders
Funder type
Industry
Merck Frosst Canada Ltd (Canada)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan | Not provided at time of registration |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Protocol article | Protocol | 24/08/2004 | Yes | No |
